Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: Results of a multicentre observational cohort study

BJU International

Volumn 103, Issue 6, 2009, Pages 776-781

  Madersbacher, Helmut ^a   Mürtz, Gerd ^b   Alloussi, Schahnaz ^c   Domurath, Burghard ^d   Henne, Thomas ^e   Körner, Iris ^f   Niedeggen, Andreas ^g   Nounla, Joseph ^h   Pannek, Jürgen ⁱ   Schulte Baukloh, Heinrich ^j   Schultz Lampel, Daniela ^k   Bock, Paul ^l   Strugala, Gerhard ^b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b APOGEPHA Arzneimittel GmbH   (Germany)

^c Krankenhaus Neunkirchen GmbH   (Germany)

^d Werner Wicker Hospital   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNFALLKRANKENHAUS BERLIN   (Germany)

^h RUHR UNIVERSITY BOCHUM   (Germany)

ⁱ University Hospital   (Germany)

^j HUMBOLDT UNIVERSITY   (Germany)

^k Hospital of Villingen   (Germany)

^l IFAG CRO   (Switzerland)

more..

Author keywords

Children; Myelomeningocele; Neurogenic detrusor overactivity; Oxybutynin; Propiverine; Spinal cord injury

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPIVERINE;

ACCOMMODATION DISORDER; ADOLESCENT; ADULT; APPETITE; ARTICLE; BLADDER CAPACITY; BLADDER PRESSURE; BRAIN DAMAGE; BRAIN HYPOXIA; CEREBRAL PALSY; CHILD; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; CYSTOMETRY; DECREASED APPETITE; DEFECATION DISORDER; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ENCEPHALITIS; FATIGUE; FEMALE; FLUSHING; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGOMYELOCELE; MULTIPLE SCLEROSIS; MYELOLIPOMA; NAUSEA; NEUROGENIC BLADDER; OBSERVATIONAL STUDY; OVERACTIVE BLADDER; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; SPINAL CORD INJURY; TERATOMA; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URODYNAMICS; VOMITING; XEROSTOMIA;

ADOLESCENT; BENZILATES; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INFANT; MALE; MANDELIC ACIDS; MENINGOMYELOCELE; MUSCARINIC ANTAGONISTS; SEVERITY OF ILLNESS INDEX; SPINAL CORD INJURIES; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 61349147687     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08093.x     Document Type: Article

References (22)

1. Bauer SB. The management of the myelodysplastic child: a paradigm shift. BJU Int 2003 92 (Suppl. 1 23 8
2. Hehir M, Fitzpatrick JM. Oxybutynin and the prevention of urinary incontinence in spina bifida. Eur Urol 1985 11 : 254 6
3. Lopez Pereira PL, Martinez Urrutia MJ, Jaureguizar E. Pharmacological therapy in neuropathic bladder. In Esposito C, Guys JM, Gough D, Savanelli A, Pediatric Neurogenic Bladder Dysfunction. Berlin : Springer, 2006 : 169 83
4. Ferrara P, D'Aleo CM, Tarquini E et al. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. BJU Int 2001 87 : 674 8
5. Madersbacher H, Halaska M, Voigt R, Alloussi S, Höfner K. A placebo-controlled multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999 84 : 646 51
6. Stöhrer M, Mürtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ. Propiverine compared to oxybutynin in neurogenic detrusor overactivity - Results of a randomized, double-blind, multicenter, clinical study. Eur Urol 2007 52 : 235 42
7. Marschall-Kehrel D, Mürtz G, Kramer G, Jünemann KP, Madersbacher H. An empirical treatment algorithm for incontinent children. J Urol 2004 171 : 2667 71
8. Schulte-Baukloh H, Mürtz G, Henne T, Michael T, Miller K, Knispel HH. Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis. BJU Int 2006 97 : 355 8
9. Grigoleit U, Mürtz G, Laschke S et al. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity - a retrospective study. Eur Urol 2006 49 : 1114 21
10. Sussmann D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002 18 : 177 84
11. Benson K, Hartz A. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000 342 : 1878 86
12. Bellach BM. Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP). Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2000 43 : 468 75
13. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002 21 : 167 78
14. McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol 1981 126 : 205 9
15. Fielding S, Fayers PM, Loge JH, Jordhoy MS, Kaasa S. Methods for handling missing data in palliative care research. Palliative Med 2006 20 : 791 8
16. Heikel PE, Parkkulainen KV. Vesicoureteral reflux in children. Ann Radiol 1966 9 : 37 40
17. Concato J, Shah N, Horwitz RI. Randomized, controller trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000 342 : 1887 92
18. Madersbacher H, Mürtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 2001 19 : 324 35
19. Ghoniem GM, Shoukry MS, Hassouna ME. Detrusor properties in myelomeningocele patients: in vitro study. J Urol 1998 159 : 2193 6
20. Goessl C, Knispel HH, Fiedler U, Härle B, Steffen-Wilke K, Miller K. Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia. Urology 1998 51 : 94 8
21. Franco I, Horowitz M, Grady R et al. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. J Urol 2005 173 : 221 5
22. Andersson KE, Appell R, Cardozo L et al. Pharmacological treatment of urinary incontinence. In Abrams P, Cardozo L, Khoury S, Wein A, Incontinence, 3rd edn. Plymouth : Health Publishers, 2005 : 809 54